The research behind Qmax Prostate

Evidence-based ingredients for age-related prostate support. Pharmaceutical-grade manufacturing. Reviewed by urologists.

At Sunn Biolabs, every formulation begins with peer-reviewed evidence. Our approach isn't to assemble whatever ingredients are trending — it's to build formulas around actives that have been studied in the populations we serve, manufacture them to pharmaceutical-grade standards, and refine them with input from practicing urologists. This page summarizes the published research behind our formula for age-related prostate support, Qmax Prostate, with links to the original studies on PubMed.

These statements have not been evaluated by the Food and Drug Administration. Qmax Prostate is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any new supplement.

BUILT ON SCIENCE  |  CLINICALLY INFORMED  |  UNCOMPROMISINGLY CLEAN

Cleveland Clinic  ·  UCLA  ·  Cedars-Sinai  ·  Queen's University  ·  Providence  ·  Keck Medicine of USC

Members of our Medical Advisory Board and formulation consultants hold academic and clinical appointments at these institutions.

ON THIS PAGE

• About benign prostatic hyperplasia (BPH)
• The research behind Qmax Prostate — ingredient by ingredient
• What makes Qmax Prostate different
• Part of a multi-modal approach
• Full references

About BPH

What is benign prostatic hyperplasia, and why does it matter after 50?

An age-related condition affecting the majority of older men

Benign prostatic hyperplasia (BPH) is the non-cancerous, age-related enlargement of the prostate gland. It is one of the most common conditions of aging in men. Foundational autopsy data from Berry and colleagues established that histological prevalence rises sharply with age — approximately 8% of men in their 40s, about 50% of men in their 60s, and roughly 80% of men in their 80s have histologically identifiable BPH [1]. Modern epidemiologic work confirms that clinical BPH with lower urinary tract symptoms (LUTS) follows a similar age-dependent trajectory, with lifetime risk of moderate-to-severe LUTS approaching 25% by age 80 [2].

Roehrborn's landmark review describes how BPH produces urinary symptoms through two overlapping mechanisms: a static component (physical enlargement of the prostate compressing the urethra) and a dynamic component (alpha-adrenergic smooth-muscle tone at the bladder neck and prostate) [3]. Typical symptoms include weak urinary stream, incomplete emptying, straining, urinary frequency, urgency, and nighttime wake-ups (nocturia).

BPH is not CP/CPPS

BPH is frequently confused with chronic prostatitis / chronic pelvic pain syndrome (CP/CPPS), but the two conditions are distinct. CP/CPPS typically affects younger men (under 50), is characterized primarily by pelvic and perineal pain rather than obstructive urinary symptoms, and has a different clinical evidence base. BPH, by contrast, is age-related, driven by prostatic enlargement and smooth-muscle tone, and is evaluated using a different standard outcome measure. Men with pelvic pain as a primary complaint should speak with their urologist about whether CP/CPPS evaluation is appropriate — Qmax Prostate is formulated for BPH-related urinary symptoms, not for pelvic pain syndromes.

The standard measure: IPSS

The International Prostate Symptom Score (IPSS) — also known as the American Urological Association Symptom Index (AUA-SI) — was developed and validated by Barry and colleagues in 1992 and has been the standard outcome measure for BPH clinical trials for over 30 years [4]. It is a 7-item patient-reported instrument covering incomplete emptying, frequency, intermittency, urgency, weak stream, straining, and nocturia, plus a quality-of-life question. When we cite BPH clinical trials on this page, "improvement in IPSS" is the outcome measure referenced.

The clinical framework: AUA 2023 BPH Guideline

The American Urological Association's 2023 BPH Guideline Amendment is the current evidence-based framework for managing male LUTS attributed to BPH [5]. It describes a stepwise range of options spanning watchful waiting and lifestyle modification for mild symptoms, through medical therapy (alpha-blockers, 5-alpha-reductase inhibitors, combination therapy), minimally invasive procedures, and surgery for more advanced disease.

Qmax Prostate is designed to fit within the early / lifestyle / watchful-waiting end of this spectrum — not to replace medical therapy or urological care for men with moderate-to-severe symptoms.

The research behind Qmax Prostate

What's in the formula, and what's the evidence?

Beta-Sitosterol — the lead ingredient, strongest BPH evidence

Beta-sitosterol is a plant phytosterol (structurally similar to cholesterol) found in small amounts across many plant foods. Of all the ingredients in Qmax Prostate, beta-sitosterol has the strongest body of randomized, placebo-controlled clinical evidence in men with BPH-related urinary symptoms. This is why we lead with it, rather than with the more familiar saw palmetto.

The anchor systematic review. Wilt and colleagues' Cochrane systematic review of beta-sitosterol for BPH pooled four randomized, placebo-controlled, double-blind trials covering 519 men. The review concluded that non-glucosidic beta-sitosterols were associated with a meaningful improvement in urinary symptom scores (weighted mean difference in IPSS of roughly 4.9 points), along with improvements in peak urinary flow and reduced post-void residual volume, compared with placebo [6].

The pivotal Lancet RCT. Berges and colleagues' 6-month double-blind placebo-controlled trial, published in The Lancet in 1995, randomized 200 men with symptomatic BPH to 20 mg of beta-sitosterol three times daily or placebo. The beta-sitosterol group showed significantly greater improvement in modified Boyarsky and IPSS symptom scores, peak urinary flow, and post-void residual volume than the placebo group [7]. A subsequent open-label 18-month follow-up reported that benefits on symptom score, quality-of-life, and flow measures were largely maintained in men who continued beta-sitosterol [8].

The German BPH-Phyto Study Group RCT. Klippel and colleagues' multicenter double-blind placebo-controlled trial in 177 BPH patients, published in the British Journal of Urology in 1997, found an adjusted between-group difference in IPSS of roughly 5.4 points favoring beta-sitosterol over placebo, plus improvements in quality-of-life index, peak urinary flow, and post-void residual volume [9].

Mechanism of action. Beta-sitosterol's proposed mechanisms for BPH benefit include inhibition of 5-alpha-reductase (the enzyme that converts testosterone to DHT, the androgen driving prostate growth), anti-inflammatory effects on prostatic stromal tissue, and modulation of prostatic growth-factor signaling. Qmax Prostate uses a standardized beta-sitosterol extract (40%).

Pygeum africanum (African plum bark)

Pygeum africanum, sometimes called African plum or Prunus africana, is a bark-derived extract with a long European clinical history in BPH.

The Cochrane systematic review. Wilt and colleagues' Cochrane review of Pygeum africanum for BPH pooled 18 randomized controlled trials covering 1,562 men. Men receiving Pygeum were more than twice as likely to report overall symptomatic improvement than men on placebo (relative risk approximately 2.1), with reductions in nocturia of roughly 19% and in residual urine volume of roughly 24% versus placebo. Pygeum was well-tolerated [10].

The peer-reviewed meta-analysis. Ishani and colleagues' quantitative meta-analysis of the same 18 RCTs, published in the American Journal of Medicine, reached concordant conclusions: Pygeum africanum was associated with moderate improvement in urologic symptoms and flow measures compared with placebo, with a favorable tolerability profile. The authors noted limitations including short study durations and variable pharmacological preparations across trials [11].

Dosing equivalence. Chatelain and colleagues' randomized parallel-group trial compared Pygeum africanum 50 mg twice daily versus 100 mg once daily in symptomatic BPH; both regimens showed equivalent efficacy and safety over 2 months, with sustained benefit through a 12-month open-label extension [12].

Mechanism of action. Proposed mechanisms for Pygeum include inhibition of basic fibroblast growth factor (bFGF) and stromal proliferation, 5-alpha-reductase modulation, anti-inflammatory activity via leukotriene B4 inhibition, and alpha-adrenergic modulation. Qmax Prostate uses a standardized Pygeum africanum extract (≥2% sterols).

Rye Grass / Flower Pollen Extract

Flower pollen extract — derived from rye grass pollen, often known in the research literature as Cernilton or in commerce as Graminex — has been studied in BPH for several decades.

The systematic review. MacDonald and colleagues' systematic review, together with the parallel Wilt Cochrane review, pooled four RCTs of Cernilton pollen extract in men with BPH [13] [14]. The evidence is split by outcome, and honest framing matters here:

• Positive for subjective symptoms. Cernilton was associated with improved self-rated urinary symptoms versus placebo (weighted relative risk 2.40) and with reduced nocturia (relative risk 2.05).
• Null for urinary flow rates. Cernilton was not associated with improved peak urinary flow rates, reduced post-void residual volume, or reduced prostate size versus placebo.

In other words: men taking Cernilton-type pollen extract in these trials reported feeling better and waking up less at night, but their objective uroflow measurements did not show a significant change. Both parts of that finding matter, and we include pollen extract in Qmax Prostate for its role in the symptomatic and nocturia-related domains of the formula rather than as a flow-rate active.

Saw Palmetto (Serenoa repens)

Saw palmetto has the longest history and the widest name recognition of any BPH phytotherapy — but it is also the ingredient whose clinical evidence has been most substantially weakened by modern high-quality trials. We include it here because it is a characterized, traditionally-used prostate-support ingredient with a defined mechanism of action, but we do not claim clinical efficacy for it in Qmax Prostate. The honest story of the evidence:

Earlier European trials were generally positive. The 1998 Wilt meta-analysis of 18 saw palmetto RCTs (mean duration 9 weeks) concluded that saw palmetto extract was associated with modest improvements in urologic symptoms and flow measures compared with placebo, with efficacy similar to finasteride [15]. Many of these trials used the Permixon lipidosterolic extract.

Modern high-quality trials are largely null. The NIH-funded CAMUS trial, published in JAMA in 2011, randomized 369 men with moderate BPH-related LUTS to escalating doses (up to 3× 320 mg/day) of saw palmetto fruit extract or placebo for 72 weeks. Saw palmetto was not associated with greater improvement in the American Urological Association Symptom Index than placebo [16]. The 2012 Cochrane review of saw palmetto for BPH (32 RCTs, 5,666 men) reached a concordant conclusion: Serenoa repens at standard, double, and triple doses was not associated with greater improvement in urinary flow measures, IPSS, or prostate size than placebo [17].

Mechanism is characterized. Suzuki and colleagues' mechanistic review describes saw palmetto's activity in the lower urinary tract, including inhibition of 5-alpha-reductase, alpha-1 adrenergic receptor modulation, muscarinic receptor binding in bladder tissue, and anti-inflammatory effects on prostatic tissue [18].

Our honest position on saw palmetto. Saw palmetto has a long tradition of use in supporting prostate health. In modern controlled clinical trials, saw palmetto monotherapy has not consistently demonstrated greater symptom improvement than placebo. We include it in Qmax Prostate for its traditional use and characterized mechanistic activity on prostatic tissue, not as a clinically validated efficacy claim. Our lead evidence ingredient is beta-sitosterol.

Bromelain and Papain — formulation synergy and enzyme support

Bromelain (a proteolytic enzyme from pineapple stem) and papain (a proteolytic enzyme from papaya) round out the Qmax Prostate formula. Their role is not as BPH-specific actives — there are no direct clinical trials of bromelain or papain in BPH, and we do not imply otherwise. They are included for two well-documented purposes:

Proteolytic and anti-inflammatory support. A 2012 review in Biotechnology Research International summarized bromelain's proteolytic, anti-inflammatory, and anti-edematous properties across multiple therapeutic contexts [19]. A 2004 review of bromelain in osteoarthritis reported that oral bromelain was associated with improvements in pain and swelling across early-phase clinical studies [20]. Papain has a similar proteolytic and traditional digestive-enzyme profile, and clinical work with papaya-derived preparations has shown associations with improvements in gastrointestinal tolerance [21].

Formulation synergy with plant extracts. Proteolytic enzymes are traditionally paired with plant-extract formulas to support the overall absorption and tolerance profile of the co-administered actives. We include bromelain and papain in Qmax Prostate on that formulation basis — and to contribute to the formula's gastrointestinal tolerability, which matters for men who take a daily supplement year after year.

What makes Qmax Prostate different

How Qmax Prostate differs from generic "prostate support" supplements

Led by the strongest-evidence ingredient, not the most familiar one

Most BPH-oriented supplements lead with saw palmetto because it's the most recognized name. Qmax Prostate doesn't. We lead with beta-sitosterol — the ingredient in the formula with the strongest direct randomized-controlled-trial evidence in men with BPH-related urinary symptoms (Wilt Cochrane systematic review, Berges 1995 Lancet RCT, Klippel 1997 BJU RCT). This is a deliberate, genre-breaking formulation choice: we build around the ingredient the evidence actually supports, then include saw palmetto for its traditional use and mechanistic rationale rather than as the lead active.

A multi-ingredient BPH-targeted formula

Qmax Prostate combines six complementary actives in a single proprietary blend of approximately 460 mg per tablet, taken as 1 tablet twice daily:

• Beta-Sitosterol (40%) — lead evidence ingredient (Wilt Cochrane, Berges, Klippel)
• Pygeum africanum (standardized, ≥2% sterols) — Cochrane-reviewed BPH phytotherapy
• Rye Grass / Flower Pollen Extract — studied for symptomatic and nocturia benefit in BPH
• Saw Palmetto (standardized, ≥45% essential oils) — traditional use and characterized mechanism
• Bromelain — proteolytic / anti-inflammatory enzyme adjunct
• Papain — proteolytic / digestive-enzyme adjunct

Pharmaceutical-grade manufacturing

Qmax Prostate is manufactured in a GMP-certified facility to pharmaceutical-grade quality standards. Each batch is assayed for ingredient identity, potency, and contaminants before it leaves the facility. This is not the standard across the dietary supplement industry — it's the standard Sunn Biolabs sets because our customers are men who deserve formulas made to the same rigor as prescription manufacturing.

Refined by a Medical Advisory Board

Qmax Prostate's formulation is reviewed and refined by Sunn Biolabs' Medical Advisory Board, a group of practicing urologists with expertise in BPH, lower urinary tract symptoms, and men's urologic health. Our MAB reviews ingredient selection, dosing, manufacturing protocols, and clinical evidence on an ongoing basis.

Part of a multi-modal approach

The AUA 2023 BPH Guideline describes BPH management as a stepwise continuum [5]. The options, from least to most invasive, include:

• Watchful waiting for men with mild symptoms or minimal bother;
• Lifestyle modification — fluid timing, caffeine and alcohol reduction, bladder training, pelvic-floor support;
• Dietary supplementation with evidence-informed phytotherapy (where Qmax Prostate sits);
• Alpha-blockers (e.g., tamsulosin) for symptom relief via smooth-muscle relaxation;
• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) for prostate-volume reduction over 6–12 months;
• Combination medical therapy for men with larger prostates or higher symptom burden;
• Minimally invasive procedures and surgical therapies for men with severe symptoms, retention, or medical-therapy failure.

Qmax Prostate is designed to support men at the early end of that spectrum — alongside lifestyle modification, during watchful waiting, or as a complement to medical guidance. It is not a replacement for professional urological evaluation, and it is not a substitute for prescription medical therapy in men who need it. Men experiencing progressive urinary symptoms, urinary retention, blood in the urine, or any sudden change in urinary function should see a urologist promptly.

Full references

All citations are peer-reviewed and PubMed-indexed. Click a PubMed ID (PMID) to read the original paper.

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3):474–9. PMID: 6206240
2. Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms: prevalence and incident rates. Urol Clin North Am. 2016;43(3):289–97. PMID: 27476122
3. Roehrborn CG. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol. 2005;7 Suppl 9:S3–S14. PMID: 16985922
4. Barry MJ, Fowler FJ Jr, O'Leary MP, et al. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148(5):1549–57. PMID: 1279218
5. Sandhu JS, Bixler BR, Dahm P, et al. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia (BPH): AUA Guideline Amendment 2023. J Urol. 2024;211(1):11–19. PMID: 37706750
6. Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1999;(3):CD001043. PMID: 10796740
7. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet. 1995;345(8964):1529–32. PMID: 7540705
8. Berges RR, Kassen A, Senge T. Treatment of symptomatic benign prostatic hyperplasia with beta-sitosterol: an 18-month follow-up. BJU Int. 2000;85(7):842–6. PMID: 10792163
9. Klippel KF, Hiltl DM, Schipp B. A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol. 1997;80(3):427–32. PMID: 9313662
10. Wilt T, Ishani A, MacDonald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2002;(1):CD001044. PMID: 11869585
11. Ishani A, MacDonald R, Nelson D, Rutks I, Wilt TJ. Pygeum africanum for the treatment of patients with benign prostatic hyperplasia: a systematic review and quantitative meta-analysis. Am J Med. 2000;109(8):654–64. PMID: 11099686
12. Chatelain C, Autet W, Brackman F. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: a randomized, double-blind study, with long-term open label extension. Urology. 1999;54(3):473–8. PMID: 10475357
13. MacDonald R, Ishani A, Rutks I, Wilt TJ. A systematic review of Cernilton for the treatment of benign prostatic hyperplasia. BJU Int. 2000;85(7):836–41. PMID: 10792162
14. Wilt T, MacDonald R, Ishani A, Rutks I, Stark G. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2000;(2):CD001042. PMID: 10796739
15. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA. 1998;280(18):1604–9. PMID: 9820264
16. Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306(12):1344–51. PMID: 21954478
17. Tacklind J, MacDonald R, Rutks I, Stanke JU, Wilt TJ. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2012;(12):CD001423. PMID: 23235581
18. Suzuki M, Ito Y, Fujino T, et al. Pharmacological effects of saw palmetto extract in the lower urinary tract. Acta Pharmacol Sin. 2009;30(3):271–81. PMID: 19262550
19. Pavan R, Jain S, Shraddha, Kumar A. Properties and therapeutic application of bromelain: a review. Biotechnol Res Int. 2012;2012:976203. PMID: 23304525
20. Brien S, Lewith G, Walker A, et al. Bromelain as a treatment for osteoarthritis: a review of clinical studies. Evid Based Complement Alternat Med. 2004;1(3):251–7. PMID: 15841258
21. Muss C, Mosgoeller W, Endler T. Papaya preparation (Caricol) in digestive disorders. Neuro Endocrinol Lett. 2013;34(1):38–46. PMID: 23524622

These statements have not been evaluated by the Food and Drug Administration. Qmax Prostate is a dietary supplement and is not intended to diagnose, treat, cure, or prevent any disease, including benign prostatic hyperplasia. Individual results may vary. Consult your healthcare provider before starting any new dietary supplement, particularly if you have a medical condition, are taking prescription medications (including alpha-blockers or 5-alpha-reductase inhibitors), or are being evaluated for urinary symptoms. Men experiencing progressive urinary symptoms, urinary retention, blood in the urine, or any sudden change in urinary function should see a urologist promptly. The peer-reviewed research cited on this page summarizes studies of individual ingredients; it does not constitute clinical evidence specific to Qmax Prostate as a finished product.